Clinical Trials Browser

Phase 3 × Observation × Other hematologic neoplasm × Clear all

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT02085408 2024-12-13

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00093470 2024-03-20

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

Phase 3 Completed

144 enrolled 8 charts

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT01039376 2019-07-30

PROLONG

Phase 3 Terminated

480 enrolled 30 charts

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT00411281 2015-09-30

Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder

Phase 3 Withdrawn

MyeloidOther hematologic neoplasm

Myeloproliferative Syndrome, Transient, Leukemia, Leukemia, Myeloid, Acute

Clinical Trials

REGAL

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

PROLONG

Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder